Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases
Articolo
Data di Pubblicazione:
2018
Citazione:
Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases / G. Fanetti, G. Marvaso, D. Ciardo, A. Rese, R. Ricotti, E. Rondi, S. Comi, F. Cattani, D. Zerini, C. Fodor, O. de Cobelli, R. Orecchia, A. Jereczek Barbara. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - 35:5(2018 May). [10.1007/s12032-018-1137-0]
Abstract:
To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan–Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0–67.2 months). No acute or late toxicity of grade > 1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Androgen deprivation therapy; Bone metastases; Castration-sensitive prostate cancer; Oligometastases; Prostate cancer; Stereotactic body radiotherapy; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Humans; Kallikreins; Male; Middle Aged; Orchiectomy; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiosurgery; Retrospective Studies; Hematology; Oncology; Cancer Research
Elenco autori:
G. Fanetti, G. Marvaso, D. Ciardo, A. Rese, R. Ricotti, E. Rondi, S. Comi, F. Cattani, D. Zerini, C. Fodor, O. de Cobelli, R. Orecchia, A. Jereczek Barbara
Link alla scheda completa: